CCI
AIMT

Columbus Circle Investors’s Aimmune Therapeutics AIMT Stock Holding History

Columbus Circle Investors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-80,818
Closed -$2M – 303
2017
Q3 		$2M Sell
80,818
-12,045
-13% -$260K 0.03% 225
2017
Q2 		$1.91M Buy
92,863
+51,604
+125% +$984K 0.03% 208
2017
Q1 		$897K Buy
+41,259
New +$846K 0.01% 252
2016
Q4 		– Sell
-61,198
Closed -$918K – 320
2016
Q3 		$918K Buy
+61,198
New +$826K 0.01% 254

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Columbus Circle Investors's AIMT Position: Q4 2017 in Review

Columbus Circle Investors sold out of Aimmune Therapeutics (AIMT) in Q4 2017, closing a stake of 80,818 shares — an estimated $2M sold.

Columbus Circle Investors first reported a position in AIMT in Q3 2016 and held it in 4 quarters. The position peaked at $2M in Q3 2017. 129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

  • Columbus Circle Investors reported no remaining Aimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 80,818 Aimmune Therapeutics shares in Q4 2017, an estimated $2M.
  • Columbus Circle Investors first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 4 quarters.
  • Columbus Circle Investors's Aimmune Therapeutics position peaked at $2M in Q3 2017.
  • 129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.